Abound Bio (United States)

Recent papers from Abound Bio (United States)

1. Human antibody VH domains targeting uPAR as candidate therapeutics for cancersFrontiers in Oncology · 2023
2. Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugateMolecular Therapy — Oncolytics · 2023
3. Human Antibody VH Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for CancersMolecular Pharmaceutics · 2023
4. Development of an efficient method for selection of stable cell pools for protein expression and surface display with Expi293F cellsCell Biochemistry and Function · 2023
5. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugatesSHILAP Revista de lepidopterología · 2023
6. Human antibodies targeting ENPP1 as candidate therapeutics for cancersFrontiers in Immunology · 2023
7. Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domainsiScience · 2022
8. Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formats2022
9. Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22Frontiers in Immunology · 2022
10. Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains2022
11. Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related DiseasesInternational Journal of Molecular Sciences · 2021
12. Protocol for constructing large size human antibody heavy chain variable domain (VH) library and selection of SARS-CoV-2 neutralizing antibody domainsSTAR Protocols · 2021
13. Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains2021
14. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infectionProceedings of the National Academy of Sciences · 2020
15. Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models2020
16. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffoldmAbs · 2020